GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Equity-to-Asset

VREOF (Vireo Growth) Equity-to-Asset : -0.06 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Vireo Growth's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-11.00 Mil. Vireo Growth's Total Assets for the quarter that ended in Sep. 2024 was $193.87 Mil. Therefore, Vireo Growth's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was -0.06.

The historical rank and industry rank for Vireo Growth's Equity-to-Asset or its related term are showing as below:

VREOF' s Equity-to-Asset Range Over the Past 10 Years
Min: -18.8   Med: 0.12   Max: 0.98
Current: -0.06

During the past 13 years, the highest Equity to Asset Ratio of Vireo Growth was 0.98. The lowest was -18.80. And the median was 0.12.

VREOF's Equity-to-Asset is ranked worse than
91.17% of 1042 companies
in the Drug Manufacturers industry
Industry Median: 0.6 vs VREOF: -0.06

Vireo Growth Equity-to-Asset Historical Data

The historical data trend for Vireo Growth's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Equity-to-Asset Chart

Vireo Growth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.61 0.26 0.02 -0.09

Vireo Growth Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.09 -0.12 -0.12 -0.06

Competitive Comparison of Vireo Growth's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vireo Growth's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Equity-to-Asset falls into.



Vireo Growth Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Vireo Growth's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-16.044/183.264
=-0.09

Vireo Growth's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Equity to Asset (Q: Sep. 2024 )=Total Stockholders Equity/Total Assets
=-11.003/193.869
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vireo Growth  (OTCPK:VREOF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Vireo Growth Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vireo Growth Business Description

Traded in Other Exchanges
Address
207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs.
Executives
Chicago Atlantic Credit Opportunities, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc 10 percent owner 420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen director 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio officer: Chief Operating Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa director, officer: Chief Administrative Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters officer: EVP of Retail C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder officer: General Counsel & CCO 3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller officer: Chief Financial Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402